This story has been updated with additional comments from Datavant. Health tech company Datavant is making moves to be a bigger player in the real-world data space. The company announced Thursday that ...
Data breaches and malware may get all the attention but real-world threats can do just as much damage, especially when you’re ...
I rely on data for clarity and risk transparency, but instinct shapes how I interpret it. My approach combines analytical ...
The rise in direct-to-patient therapeutics access via online compounding pharmacies and other direct-to-patient sales models has increased the likelihood of patients utilizing medications alongside ...
Thanks to new regulatory frameworks like the Food and Drug Administration’s Breakthrough Therapy designation, drugs are coming to market faster than ever. A 2024 analysis of drugs included in this ...
Harnessing Real-World Data and AI to Advance Research and Treatment for Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...
First, institutions must ensure that synthetic datasets are continuously recalibrated against fresh, real-world evidence. The ...
Knowing patient survival rates is critical to informing research and care delivery, particularly in the oncology space. But what if survival data is inaccurate or incomplete? Well, that could ...
With more than 2,000 citations and year-over-year growth nearing 80%, TriNetX outpaces competitors and fuels high-impact science published in top medical journals. CAMBRIDGE, Mass., Oct. 15, 2025 ...
The Tesla Semi has been a long-running project for the electric automaker. As is the Tesla way, the company has promised big things long ahead of the product actually reaching the market. Now, we’re ...
Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...
Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi and Regeneron have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results